The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
BREAKWATER: Progression-free and overall survival analyses of first-line (1L) encorafenib + cetuximab (EC) + FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer (mCRC).
 
Scott Kopetz
Stock and Other Ownership Interests - Frontier Medicines; Lutris; Navire
Consulting or Advisory Role - Alentis Therapeutics; AmMax Bio; Arcus Biosciences; AstraZeneca; AVEO; BeiGene; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb/Medarex; Carina Biotech; Clasp Therapeutics; Cytovation; Dewpoint Therapeutics; EMD Serono; Erasca, Inc; Flame Biosciences; Frontier Medicines; Genentech; Harbinger Oncology, Inc; Ikena Oncology; Iterion Therapeutics; Kivu Biosciences; Marengo Therapeutics; Pfizer; Regeneron; Roche; SageMedic; SERVIER; Shionogi; T-Cypher Bio; Tachyon Therapeutics; Transcode; XAIRA Therapeutics; Zentalis; Zentalis
Research Funding - Boehringer Ingelheim; EMD Serono; Genentech; Pfizer; Roche; Zentalis
 
Josep Tabernero
Stock and Other Ownership Interests - 1TRIALSP; Alentis Therapeutics; Oniria Therapeutics; Pangaea Oncology
Consulting or Advisory Role - Accent Therapeutics; Alentis Therapeutics; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Carina Biotech; Cartography Biosciences; Chugai Pharma; Daiichi Sankyo; F. Hoffmann LaRoche; Genentech; Johnson & Johnson/Janssen; Larkspur Biosciences Inc; Lilly; Marengo Therapeutics; Menarini; Merus; MSD; Novartis; One-carbon Therapeutics AB; Ono Pharmaceutical; Peptomyc; Pfizer; Pierre Fabre; Quantro Therapeutics; Scandion Oncology; Scorpion Therapeutics; Servier; Sotio; Syntelios AG; Taiho Pharmaceutical; Takeda Pharmaceuticals International AG; Theriva Biologics; Tolremo
 
Sara Lonardi
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Beigene; Bristol-Myers Squibb; Daiichi Sankyo; Fosun Pharma; GlaxoSmithKline; Incyte; Lilly; Merck Serono; MSD; Nimbus Therapeutics; Rottapharm Biotech; SERVIER; Takeda
Speakers' Bureau - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Incyte; Lilly; Merck Serono; MSD Oncology; Pierre Fabre; Roche; Servier
Research Funding - Amgen; AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck Serono; Roche (Inst)
 
Lin Shen
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; MSD; SERVIER; Transcenta Holding Limited
Research Funding - BeiGene (Inst)
 
Harpreet Wasan
Honoraria - Array BioPharma; Celgene; ERYTECH Pharma; Incyte; Merck KGaA; Roche/Genentech; Servier; Sirtex Medical; Zymeworks
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; ERYTECH Pharma; EXACT Therapeutics; Incyte; Jazz Pharmaceuticals/zymeworks; Nordicpharma; Pfizer; Pierre Fabre; Roche Pharma AG; Shire; Sirtex medical; Taiho Oncology; Takeda
Speakers' Bureau - Celgene; Incyte; Merck KGaA; SERVIER; Sirtex Medical
Research Funding - Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Sirtex Medical (Inst)
Expert Testimony - Bayer; Oncosil
 
Takayuki Yoshino
Honoraria - Chugai Pharma; Merck; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - Indivumed; Sumitomo Corp.
Research Funding - Bristol-Myers Squibb Japan (Inst); Caris MPI (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Eisai (Inst); Exact Sciences (Inst); FALCO biosystems Ltd. (Inst); Medical & Biological Laboratories Co., Ltd. (Inst); Merus (Inst); Miyarisan pharmaceutical (Inst); MSD (Inst); Natera (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Eric Van Cutsem
Consulting or Advisory Role - Abbvie; Agenus; ALX Oncology; Amgen; Arcus Biosciences; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Biond Biologics; Boehringer Ingelheim; Bristol-Myers Squibb; Cantargia AB; Cardiff Oncology; Corcept Therapeutics; CytomX Therapeutics; Daiichi Sankyo; ElmediX; Fortvita; Fosum; Galapagos NV; Gilead Sciences; GlaxoSmithKline; Glenmark; Incyte; Ipsen; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Lilly; Merck KGaA; Merck Sharp & Dohme; Merus; Nordic Group; Novartis; Novocure; Oncoshot; Oxford BioTherapeutics; Pfizer; Pierre Fabre; Sanofi; SERVIER; Taiho Pharmaceutical; Takeda; Trishula Therapeutics; Zuellig Pharma; Zymeworks
 
Tae Won Kim
Employment - Asan Medical Center
Research Funding - Inocras (Inst); Roche/Genentech (Inst)
 
Cathy Eng
Consulting or Advisory Role - Abbvie; Abbvie; Agenus; Amgen (I); Boehringer Ingelheim; Bristol Myers Squibb Foundation; EMD Serono; Gilead Sciences; GlaxoSmithKline; Incyte; Merck; Merus; Pfizer; Revolution Medicines; Taiho Oncology (I); Takeda
Research Funding - Gritstone Bio (Inst); Hutchison MediPharma (Inst); Janssen Oncology (Inst); Merck (Inst); Pfizer (Inst); Sumitomo Dainippon Pharma Oncology (Inst)
Travel, Accommodations, Expenses - Takeda
 
Fortunato Ciardiello
Consulting or Advisory Role - Amgen; Bayer; Merck KGaA; Pfizer; Roche/Genentech
Research Funding - Amgen (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Roche/Genentech (Inst); SERVIER (Inst); Symphogen (Inst)
 
Jayesh Desai
Consulting or Advisory Role - Amgen (Inst); Axelia Oncology; Bayer; BeiGene; Boehringer Ingelheim; Daiichi Sankyo Europe GmbH; Ellipses Pharma; GlaxoSmithKline; Incyte; Merck KGaA; Novartis; Pfizer; Pierre Fabre; Roche/Genentech
Research Funding - Amgen (Inst); AstraZeneca/MedImmune (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Roche (Inst)
 
Tim Maughan
Employment - Great Western Hospital NHS Foundation trust; University of Liverpool
Consulting or Advisory Role - AstraZeneca/MedImmune; Dpertment of Oncology, University of Oxford; Ground Truth Laboratories; Nordic Bioscience; Perspectum Diagnostics
Research Funding - Almac Diagnostics (Inst); AstraZeneca (Inst); Merck KgAA (Inst); PsiOxus Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - patent pending
 
Rona Yaeger
Consulting or Advisory Role - Alterome Therapeutics; Bayer; Erasca, Inc; Loxo@Lilly; Merck; Parabilis Medicines; Revolution Medicines
Research Funding - Boundless Bio (Inst); Daiichi Sankyo/UCB Japan (Inst); Lilly (Inst); Mirati Therapeutics (Inst); Parabilis Medicines (Inst); Pfizer (Inst); Revolution Medicines (Inst)
Other Relationship - CytoDyn
 
Tiziana Usari
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer; Viatris
 
Xiaoxi Zhang
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Elena Beyzarov
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Ave Mori
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Elizabeth Whalley
Employment - Pfizer
 
Xiaosong Zhang
Employment - Pfizer
 
Elena Elez
Honoraria - Agenus; Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Cure Teq AG; GlaxoSmithKline; Janssen; Johnson&Johnson; Lilly; Medscape; Merck; Merck Serono; MSD; Nordic Group BV; Novartis; Pfizer; Pierre Fabre; Repare Therapeutics; RIN Institute Inc.; Roche; Rottapharm Biotech; Sanofi; Seagan; SERVIER; Takeda
Consulting or Advisory Role - Agenus; Amgen; Bayer; Boehringer Ingelheim; Bristol Myers Squibb; Cure Teq AG; GlaxoSmithKline; Janssen; Johnson&Johnson; Lilly; Medscape; Merck; Merck Serono; MSD; Nordic Group BV; Novartis; Pfizer; Pierre Fabre; Repare Therapeutics Inc.; RIN Institute Inc.; Roche; Rottapharm Biotech; Sanofi; Seagan (Inst); SERVIER; Takeda
Speakers' Bureau - Agenus; Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Cure Teq AG; GlaxoSmithKline; Janssen; Johnson & Johnson; Lilly; Medscape; Merck; Merck Serono; MSD; Nordic Group BV; Novartis; Pfizer; Pierre Fabre; Repare Therapeutics; RIN Institute; Roche; Rottapharm Biotech; Sanofi; Seagan (Inst); SERVIER; Takeda
Research Funding - 1Globe Health Institute (Inst); Agenus (Inst); Amgen (Inst); Artios (Inst); AstraZeneca (Inst); Biontech Rna Pharmaceuticals Gmbh (Inst); Biontech Small Molecules Gmbh (Inst); Bristol-Myers Squibb International Corporation (Bms) (Inst); Cancer Research UK (Inst); Exelixis (Inst); Fédération Francophone De Cancérologie Digestive (Inst); Fundación CRIS Contra el Cáncer (Inst); GlaxoSmithKline (Inst); Grupo de Tratamiento de los Tumores Digestivos (TTD) (Inst); Grupo Español Multidisciplinar en Cáncer Digestivo (GEMCAD) (Inst); INCLIVA Institut d'Investigació Sanitària (Inst); InhibRx (Inst); Instituto de Salud Carlos III (ISCIII) (Inst); Istituto Fondazione AIRC di Oncologia Molecolare (IFOM) (Inst); Janssen Research & Development (Inst); Janssen-Cilag SA (Inst); Merck (Inst); Merck, Sharp & Dohme de España SA (Inst); Msd Regional Business Support Center Gmbh (Inst); Nouscom (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Agenus; Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Cure Teq AG; GlaxoSmithKline; Janssen; Johnson&Johnson; Lilly; Medscape; Merck; Merck Serono; MSD; Nordic Group BV; Novartis; Pfizer; Pierre fabre; Repare Therapeutics; RIN Institute Inc.; Roche; Rottapharm Biotech; Sanofi; Seagan; SERVIER; Takeda